The protective role of bone morphogenetic protein-8 in the glucocorticoid-induced apoptosis on bone cells
János P Kósa1, Adrián Kis, Krisztián Bácsi
11st Department of Internal Medicine of Semmelweis University, Budapest, Hungary. jkosa@bel1.sote.hu
Abstract:
One of the side effects associated with glucocorticoid therapy is glucocorticoid-induced bone loss. Glucocorticoids partly detain bone formation via the inhibition of osteoblastic function, however, the exact mechanism of this inhibition remains elusive. In this study, we examined the effect of dexamethasone, an active glucocorticoid analogue, on cell viability and expression of bone remodelling-related genes in primary mouse calvarial and cloned MC3T3-E1 osteoblasts. Using sensitive biochemical assays, we demonstrated the apoptotic effect of dexamethasone on osteoblastic cells. Then, utilizing Taqman probe-based quantitative RT-PCR technology, gene expression profiles of 111 bone metabolism-related genes were determined. As a result of dexamethasone treatment we have detected significant apoptotic cell death, and six genes, including Smad3, type-2 collagen α-1, type-9 collagen α-1, matrix metalloproteinase-2, bone morphogenetic protein-4 and bone morphogenetic protein-8 showed (BMP-8) significant changes in their expression on a time- and concentration-dependent manner. BMP-8, (a novel player in bone-metabolism) exhibited a two orders of magnitude elevation in its mRNA level and highly elevated protein concentration by Western blot in response to dexamethasone treatment. The knockdown of BMP-8 by RNA interference significantly increased dexamethasone-induced cell death, confirming a protective role for BMP-8 in the glucocorticoid-induced apoptosis of osteoblasts. Our results suggest that BMP-8 might be an essential player in bone metabolism, especially in response to glucocorticoids.
Insights
Glucocorticoid therapy causes bone loss by inducing osteoblast apoptosis. Bone morphogenetic protein-8 (BMP-8) plays a protective role, as its knockdown worsens dexamethasone-induced cell death in osteoblasts.
Area of Science:
- Bone Biology
- Endocrinology
- Cellular Biology
Background:
- Glucocorticoid therapy is associated with bone loss.
- The mechanism by which glucocorticoids inhibit osteoblast function and bone formation is not fully understood.
- Understanding these mechanisms is crucial for mitigating side effects.
Purpose of the Study:
- To investigate the effects of dexamethasone on osteoblast viability and gene expression.
- To elucidate the role of specific bone remodeling genes in glucocorticoid-induced bone loss.
- To identify potential protective mechanisms against glucocorticoid-induced apoptosis.
Main Methods:
- Primary mouse calvarial and MC3T3-E1 osteoblasts were treated with dexamethasone.
- Cell viability was assessed using biochemical assays.
- Gene expression profiles of 111 bone metabolism genes were analyzed using quantitative RT-PCR.
- Protein levels of BMP-8 were determined by Western blot.
- BMP-8 was knocked down using RNA interference.
Main Results:
- Dexamethasone induced significant apoptotic cell death in osteoblasts.
- Expression of six genes, including BMP-8, changed significantly in a time- and concentration-dependent manner.
- BMP-8 mRNA and protein levels were significantly elevated by dexamethasone treatment.
- Knockdown of BMP-8 exacerbated dexamethasone-induced osteoblast cell death.
Conclusions:
- Dexamethasone induces apoptosis in osteoblasts, contributing to glucocorticoid-induced bone loss.
- BMP-8 plays a protective role in mitigating dexamethasone-induced osteoblast apoptosis.
- BMP-8 is a key mediator in bone metabolism, particularly in response to glucocorticoids.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Osteoclasts in Bone Remodeling
Apoptosis
TGF - β Signaling Pathway
Caspases

